Prothena Corp Public (PRTA) Other Non Operating Income (2013 - 2026)
Prothena Corp Public (PRTA) posted quarterly Other Non Operating Income of $271000.0 for Q1 2026, up 293.57% year-over-year from $68856.6 in Q1 2025, and up 1331.82% quarter-over-quarter from -$22000.0 in Q4 2025.
Prothena Corp Public (PRTA) Other Non Operating Income (2013 - 2026) Analysis & Trends
Prothena Corp Public's Other Non Operating Income history runs 14 years deep, the most recent figure standing at $271000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 293.57% year-over-year to $271000.0; the TTM figure through Mar 2026 stood at $83000.0 (up 133.47% YoY), while the FY2025 annual figure was -$328000.0, down 77.3% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $271000.0, up from -$22000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $271000.0 in Q1 2026, with the low at -$327000.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$66000.0 (2024), against an average of -$64529.4.
- The sharpest annual moves came in 2023 and 2026: Other Non Operating Income plunged 4750.0% in 2023, then surged 293.57% in 2026.
- Prothena Corp Public's Other Non Operating Income stood at -$327000.0 in 2022, then surged by 37.31% to -$205000.0 in 2023, then jumped by 104.39% to $9000.0 in 2024, then tumbled by 344.44% to -$22000.0 in 2025, then jumped by 1331.82% to $271000.0 in 2026.
- Business Quant data shows PRTA's Other Non Operating Income at $271000.0 in Q1 2026, -$22000.0 in Q4 2025, and -$23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33,000.00 |
| Mar 31, 2026 | 271,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | -23,000.00 |
| Jun 30, 2025 | -143,000.00 |
| Mar 31, 2025 | -140,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | -66,000.00 |
| Jun 30, 2024 | -51,000.00 |
| Mar 31, 2024 | -77,000.00 |
| Dec 31, 2023 | -205,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -97,000.00 |
| Mar 31, 2023 | -141,000.00 |
| Dec 31, 2022 | -327,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -70,000.00 |
| Dec 31, 2021 | -16,000.00 |
| Sep 30, 2021 | -42,000.00 |